A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

January 31, 2007

Study Completion Date

February 28, 2007

Conditions
Lymphoma, B-Cell
Interventions
DRUG

ONTAK (denileukin diftitox)

Trial Locations (12)

10011

St. Vincent's Comprehensive Cancer Center, New York

14263

Roswell Park Cancer Institute, Buffalo

15224

The Western Pennsylvania Hospital, Pittsburgh

30306

Emory University, Atlanta

44106

Case Comprehensive Cancer Center, Cleveland

60612

Rush University Medical Center, Chicago

63110

Washington University Siteman Cancer Center, St Louis

90095

University of California, Los Angeles, Los Angeles

92708

Pacific Coast Hematology/Oncology, Fountain Valley

90211-1850

Tower Cancer Research Foundation, Beverly Hills

51101-1733

Siouxland Hematology-Oncology, Sioux City

07601

Hackensack University Medical Center, Hackensack

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00211276 - A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter